Myriad Genetics, Inc. (MYGN) vs Personalis, Inc. (PSNL)
- Myriad Genetics, Inc. MYGN 3.98 −8.51%
- Personalis, Inc. PSNL 15.65 −1.76%
Myriad Genetics, Inc. and Personalis, Inc. are both Diagnostics & Research companies. Personalis, Inc. is the larger, with a market value of $1.7B against $416.1M — 4.1× the size. Myriad Genetics, Inc. grew revenue faster over the last twelve months: −3.16% against −13.3%. Myriad Genetics, Inc. has the higher net margin (−14.0% vs −153.8%) and the higher return on invested capital (−19.9% vs −317.5%). Across the 18 metrics below, Myriad Genetics, Inc. leads on 14 and Personalis, Inc. on 4.
Valuation
Profitability
| Metric | MYGN | PSNL | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 68.83% | 12.69% | 50.89% |
| Operating margin | (12.22%) | (164.07%) | (8.57%) |
| Net margin | (13.96%) | (153.84%) | (6.37%) |
| Free cash flow margin | (1.76%) | (144.76%) | 0.00% |
| Return on equity | (32.54%) | (50.32%) | (2.92%) |
| Return on assets | (17.11%) | (37.55%) | (6.71%) |
| Return on invested capital | (19.92%) | (317.48%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack